Seems the NSCLC folks are starting from a tough position. Cant help thinking what would the responses be if the treatment was initiated at an earlier stage. That is when a person's immune system was more robust. Prior to the impact of cancer and drugs suppressive side effects on their immune response. It seems this is a challenge for any perspective new treatment. Kind of like attempting to resuscitate a patient when it's too late.
Ann: Encouraging Phase II TACTI-002 data reported at SITC 2020, page-11
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.5¢ | $469.8K | 1.579M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 297652 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 7500 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |